Startups channel feed – Endpoints News

Startups channel feed

Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut — with J&J's blessing

7 years ago

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia

7 years ago

Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target

7 years ago

With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding

7 years ago

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

7 years ago

Penn spinout preps for human studies of a new-model CAAR, aiming at a one-time cure for autoimmune diseases

7 years ago

The resurrection of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gamble on PhIII trials

7 years ago

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

7 years ago

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

7 years ago

Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player

7 years ago

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

7 years ago

Antisense startup Stoke Therapeutics secures another $90M in series B funding

7 years ago

Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline

7 years ago

Medicines Co execs grab a $33M A round to spin out an infectious disease outfit with a pipeline

7 years ago

Biotech vets launch a neuro startup with $54.5M to kickstart R&D

7 years ago

Versant-backed Gotham Therapeutics launches with $54M round and a new way to connect on mRNA

7 years ago

MIT spinout from Sangeeta Bhatia’s lab gets a $22M round to develop new disease and drug sensors

7 years ago

GSK hands cash and tech to a biotech startup pointed down the same R&D road they want to travel

7 years ago

Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, Novartis

7 years ago

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

7 years ago

Three years after selling Acerta to AstraZeneca in $7B deal, Dave Johnson is back at the helm of a biotech startup

7 years ago

Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects

7 years ago

Atlas, F-Prime provide launch money for Akrevia — a little biotech with big plans to design better drugs

7 years ago

Lyra pockets $29.5M to push ear, nose, throat applications of implant tech from Langer, Whitesides

7 years ago

First page Previous page 60 61 626364 65 66 Next page Last page